1What it is
Petrelintide is Zealand Pharma's long-acting amylin analogue, designed as a weekly injection for obesity. Zealand (Denmark) also discovered lixisenatide and co-develops survodutide. In 2025 Roche entered a large collaboration with Zealand to co-develop and commercialise petrelintide, both alone and in combination with Roche's own incretin candidates †. That deal reflects the broader industry bet that amylin analogues could offer GLP-1-like weight loss with better tolerability and better preservation of lean mass.
The amylin class is small: pramlintide (profile 65) is the only approved member; cagrilintide (Novo Nordisk, in the CagriSema combination) is the most advanced investigational one; eloralintide (profile 67) is Lilly's. Petrelintide's claimed differences are a formulation stable at physiological pH, which matters for combining it in one pen with a GLP-1 drug, and a receptor profile closer to native amylin.
2How it's thought to work
Amylin is released with insulin after meals and signals to the brain that eating is under way. Petrelintide mimics this:
3What the research shows
Weight loss in overweight/obesity
Phase 2b — ZUPREME-1 and ZUPREME-2
Combination with incretins
Lean mass, nausea comparison with GLP-1 agonists
4Reported side effects and interactions
Literature-reported
nausea, vomiting, decreased appetite and other GI effects, reported as mostly mild to moderate in phase 1; injection-site reactions. No serious safety signal reported publicly, but exposure is small and short.Community-reported
very limited; petrelintide is not yet widely available in the grey market. Any product sold under this name should be treated as of uncertain identity.Theoretical (class). amylin analogues slow gastric emptying and could delay oral drug absorption; pramlintide's experience suggests any added hypoglycaemia risk comes only in combination with insulin. Long-term effects on the calcitonin receptor (bone, calcium handling) are a theoretical question for all compounds in this class and have not been characterised for petrelintide. Anti-drug antibodies †.
Interactions. none established. Likely additive with GLP-1 (the intended combination).
Markers researchers commonly monitor
No compound-specific markers are established; the trial protocols and class physiology suggest:
| Marker | Why it's watched |
|---|---|
| Weight, waist circumference and body composition (DEXA/bioimpedance) | the lean-mass question is the key one for this class. |
| HbA1c and fasting glucose | amylin analogues improve post-meal glucose; relevant in ZUPREME-2. |
| Serum calcium and bone markers | a theoretical calcitonin-receptor consideration; not routinely needed but a baseline is reasonable in long-term use. |
| Lipid panel and blood pressure | expected to improve with weight loss. |
| eGFR and creatinine | dehydration from GI effects. |
| CBC and CMP | general baseline for an investigational injected compound. |
Free for everyone. Safety information is never behind a paywall.
5Reconstitution and handling
Investigational product; trial material is a liquid formulation stable at neutral pH. If grey-market material is encountered, standard practice applies: with , swirl gently, refrigerate, protect from light. Dose units in trials are milligrams; the calculator helps avoid unit confusion.
Open in calculator, pre-loaded →6Commonly studied alongside
Planned with CT-388 (GLP-1/GIP). Class comparators: cagrilintide (and CagriSema with semaglutide), eloralintide, pramlintide. Community discussion sometimes pairs amylin analogues with semaglutide or tirzepatide, mirroring CagriSema; there is no petrelintide trial of this.
Informational cross-links. Not stack recommendations.
7Regulatory status by region
| Region | Status (checked —) |
|---|---|
| United States | Not FDA-approved; investigational (IND). Not permitted for compounding |
| European Union | Not authorised; investigational |
| United Kingdom | Not licensed |
| Australia | Not approved |
| South Africa | Not registered |
| Sport | Not specifically listed by WADA; as a non-approved substance it falls under S0 † |
8Open questions
- Does the phase 1 trajectory hold at 28 and 52 weeks, and what is the plateau?
- Is lean-mass preservation real when measured by DEXA against a GLP-1 comparator?
- Tolerability versus semaglutide at matched weight loss.
- Whether a fixed-dose combination with a GLP-1/GIP adds materially beyond either alone.
9References
- 1Zealand Pharma (2024). Petrelintide (ZP8396) phase 1 multiple-ascending-dose results in adults with overweight or obesity — company announcement and congress presentation [verify peer-reviewed publication]. PubMed
- 2Zealand Pharma / Roche (2025). Collaboration and co-development agreement for petrelintide — press release [verify]. PubMed
- 3ClinicalTrials.gov. ZUPREME-1 and ZUPREME-2: phase 2 trials of petrelintide in overweight/obesity and type 2 diabetes [verify identifiers]. PubMed
- 4Hay DL et al. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. PubMed · DOI
- 5Boyle CN, Lutz TA, Le Foll C (2018). Amylin — its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. PubMed · DOI
References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.
† Being confirmed by our reviewers against current sources.
10Community
Threads and protocols are visible to members. Joining is free.
Self-reported side effects Phase 2
11Page history
Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.